Editor's Note: Missed pill correspondence
Interested readers may wish to note that there has been a letter 1 from the Clinical Effectiveness Unit (CEU) published in the Lancet, in response to the April Editorial 2 by Diana Mansour and Ian Fraser.
The main points of this letter can be summarised as follows: The authors believe that most women know the name and type of their pill and would be able to apply the recommendations. They believe having different rules for 20 and 30 µg ethinylestradiol pills minimises intervention and inconvenience for the maximum number of women. They state a pill has been missed only when 24 hours have elapsed after the scheduled time. They did not review the three studies cited by Mansour and Fraser as suggesting caution about extending the pill-free interval beyond 7 days; two were published after the World Health Organization recommendations were developed. Finally, the Faculty of Family Planning and Reproductive Health Care's philosophy is to be guided by evidence, not fear of litigation.
A comment in response to the letter has been placed on the Lancet's website. 3 For our readers' convenience, we have permission to reproduce it in full below. To examine women's views and knowledge regarding this issue we produced a short anonymous questionnaire for women using DMPA who attend contraception and sexual health clinics in Newcastle-upon-Tyne. It was given to all women prior to their consultation appointment at three clinics between January and June 2005.
All 64 patients to whom the questionnaire was given completed it, and their ages ranged from 17 to 46 (mean, 25.8) years. They had been using DMPA for between 3 months and 9 years (mean duration of use, 2.6 years).
Of these patients, 53 (83%) were aware of the possible effects of DMPA on BMD, and all of these women felt that their concerns had been discussed. Four of these patients (all in their twenties) were considering a change of contraception following reading about the CSM advice in the media or as a result of discussing this issue with a health care professional. One woman was definitely going to change her method of contraception to a progestogen-only implant.
Those women who were not considering a change to their contraception (i.e. 90.5% of those aware of the link with reduced BMD) cited various reasons for continuing DMPA including:
G the potential reversibility of BMD changes G researching the topic themselves and finding the evidence weak G belief that they were not at risk of osteoporosis G worrying about forgetting pills G concern related to side effects with other forms of contraception. There were 11 patients who stated that they were not aware of any effects DMPA may have on bone health. This was 17% of the sample, which is rather concerning. All the patients said they had been given a Family Planning Association leaflet on injectables before or at the start of DMPA use, which highlights the importance of ensuring patient understanding within the consultation rather than relying on written information which may not be read, understood or retained. All the women in this group had the effects of DMPA on BMD discussed with them after completion of the questionnaire and all decided to continue using this method of contraception.
As health professionals, it is easy to presume that women attending for repeat prescriptions are aware of issues regarding their contraceptive method. However, patient choice can only be informed if it is based on current evidence, even if this involves sharing uncertainty regarding guidance.
From this small audit only one woman planned to change her contraceptive method from DMPA, although four others were considering a change (8% of the total). We do not know, however, how many women have chosen to start other birth control methods in the light of this information or those who have discontinued DMPA and are now using less effective methods. Overall DMPA still remains a popular choice for women wanting a highly effective yet reversible method of contraception, and the majority of established users surveyed wish to continue its use. A recently completed re-audit of documentation of female sterilisation carried out in our department has identified areas where there is room for further improvement in our practice. It is our experience that the awareness of the standards set out in the RCOG's guidelines was not enough on its own to facilitate changes towards improving the quality of communication and to ensure that our documentation process was fully compliant with the RCOG's guidelines.
Ruth
Sterilisation is a major cause of litigation involving gynaecological practice, accounting for 25% of all claims notified to the Medical Defence Union. 3 In order to minimise the risk of litigation, the need for adequate documentation and the use of a checklist as an important part of informed consent procedures was identified in a previous study. 4 The present authors have now demonstrated that the introduction of a standardised proforma can significantly improve the level of compliance with the RCOG's guidelines by improving the quality of documentation. 1 If our ultimate goal is to improve the quality of care and thereby reduce the high level of complaints and litigation associated with female sterilisation, then the available evidence would suggest that units providing the female sterilisation service should seriously consider the use of a standardised proforma that would ensure that a consistent and adequate information as recommended by the RCOG is provided to all patients requesting sterilisation. 
